跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 330,061 条关于
“Lundbeck A/S”
全部
330,061
临床试验
278,393
药物
6,813
机构
4,112
资讯
40,743
去年
Vyepti (Eptinezumab) Shows Positive Phase III Results in Asian Migraine Patients
去年
Multiple System Atrophy Pipeline Shows Promise with 22+ Therapies in Development as FDA Grants Fast Track Designations
去年
Longboard Pharmaceuticals Advances Bexicaserin for Dravet Syndrome
6个月前
Lundbeck Reports Positive Phase 1b Results for Lu AF28996 in Advanced Parkinson's Disease
去年
Longboard Pharmaceuticals Initiates Phase 3 Trial of Bexicaserin for Dravet Syndrome
去年
Lundbeck Presents Phase II Data for Amlenetug in Multiple System Atrophy at International Congress
去年
Lundbeck Presents Bexicaserin Data for Developmental and Epileptic Encephalopathies at AES Annual Meeting
去年
Lundbeck Restructures Global Operations, Exits 27 Markets Through Strategic Partnership Model
去年
Lundbeck Partners with DCAI to Accelerate Brain Disorder Drug Discovery Using Gefion AI Supercomputer
去年
Lundbeck Presents Promising Data on Amlenetug for Multiple System Atrophy at MDS Congress
第 1 页,共 4075 页
上一页
下一页